XVR031

XVR031 is a next-generation single-domain antibody (VHH or nanobody) therapy developed by ExeVir Bio for the treatment and prevention of COVID-19 and for broader pandemic preparedness. Derived from llama-derived antibodies, XVR031 is designed to target highly conserved epitopes on the SARS-CoV-2 spike protein, aiming to maintain potent neutralization against a wide range of emerging viral variants. The candidate is engineered for high stability and ease of manufacturing, making it suitable for global distribution and use in diverse clinical settings, including for immunocompromised individuals who may not achieve adequate protection from traditional vaccines. XVR031 is part of ExeVir's broader strategy to develop a toolbox of broadly neutralizing antibodies against coronaviruses and other high-threat pathogens.